Predictive Oncology - POAI Stock Price Target and Predictions

  • Consensus Rating: N/A
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00 %
  • Number of Analysts: 0
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$0.41
▲ +0.01 (2.52%)

This chart shows the closing price for POAI by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Predictive Oncology Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for POAI and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for POAI

Analyst Price Target is $0.00
▼ -100.00% Downside Potential
This price target is based on 0 analysts offering 12 month price targets for Predictive Oncology in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $0.41.

This chart shows the closing price for POAI for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is N/A

The current consensus among 0 investment analysts is to n/a stock in Predictive Oncology. This rating changed within the last month from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/17/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/15/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/14/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/14/2022
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/12/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/10/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/9/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/9/2022

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
11/16/2021Litchfield Hills ResearchReiterated RatingBuyMedium
6/30/2021HC WainwrightInitiated CoverageBuy$5.00High
2/1/2021Litchfield Hills ResearchInitiated CoverageBuy$3.00Low
(Data available from 12/10/2017 forward)

News Sentiment Rating

0.66 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 1 very positive mentions
  • 3 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
5/14/2022
  • 1 very positive mentions
  • 3 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
6/13/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/13/2022
  • 1 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
8/12/2022
  • 2 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
9/11/2022
  • 1 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
10/11/2022
  • 3 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
11/10/2022
  • 1 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
12/10/2022

Current Sentiment

  • 1 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Very Positive

Predictive Oncology logo
Predictive Oncology Inc., a knowledge-driven company, focuses on developing personalized cancer therapies using artificial intelligence (AI) primarily in the United States. The company operates in four segments: Helomics, zPREDICTA, Soluble, and Skyline. The Helomics segment offers clinical testing services comprising tumor drug response testing and genomic profiling tests; and contract research services through patient-centric drug discovery using active learning technology for discovery, clinical and translational research, clinical trials, and diagnostic development and validation. The zPREDICTA segment develops organ-specific disease models that provide 3D reconstruction of human tissues representing each disease state and mimicking drug response for testing of anticancer agents. The Soluble segment provides services using High-Throughput Self-Interaction Chromatography, a self-contained, automated system that conducts high-throughput, self-interaction chromatography screens using additives and excipients that are included in protein formulations for soluble and physically stable formulations for biologics. This segment also offers protein stability analysis services; protein solubility kits that allow rapid identification of soluble formulations; and proprietary technologies for bacterial endotoxin detection and removal. The Skyline segment provides STREAMWAY System, a wall-mounted fully automated system, which virtually eliminates staff exposure to blood, irrigation fluid, and other infectious fluids found in the healthcare environment. It also offers research and development services; and media that help cancer cells grow outside the patient's body and retain their DNA/RNA and proteomic signatures. The company was formerly known as Precision Therapeutics Inc. and changed its name to Predictive Oncology Inc. in June 2019. Predictive Oncology Inc. was incorporated in 2002 and is based in Eagan, Minnesota.
Read More

Today's Range

Now: $0.41
Low: $0.40
High: $0.45

50 Day Range

MA: $0.32
Low: $0.24
High: $0.55

52 Week Range

Now: $0.41
Low: $0.21
High: $1.10

Volume

127,714 shs

Average Volume

541,642 shs

Market Capitalization

$31.98 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.26

Frequently Asked Questions

What sell-side analysts currently cover shares of Predictive Oncology?

The following sell-side analysts have issued stock ratings on Predictive Oncology in the last year:
View the latest analyst ratings for POAI.

What is the current price target for Predictive Oncology?

0 Wall Street analysts have set twelve-month price targets for Predictive Oncology in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for Predictive Oncology in the next year.
View the latest price targets for POAI.

What is the current consensus analyst rating for Predictive Oncology?

Predictive Oncology currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for POAI.

What other companies compete with Predictive Oncology?

Other companies that are similar to Predictive Oncology include Eargo, Nutriband, Milestone Scientific, Conformis and Sientra. Learn More about companies similar to Predictive Oncology.

How do I contact Predictive Oncology's investor relations team?

Predictive Oncology's physical mailing address is 2915 COMMERS DRIVE SUITE 900, EAGAN MN, 55121. The medical instruments supplier's listed phone number is (651) 389-4800 and its investor relations email address is [email protected] The official website for Predictive Oncology is www.precisiontherapeutics.com. Learn More about contacing Predictive Oncology investor relations.